Cranberry fruit powder (FlowensTM) improves lower urinary tract symptoms in men: a double-blind, randomized, placebo-controlled study.

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F16%3A33161875" target="_blank" >RIV/61989592:15110/16:33161875 - isvavai.cz</a>

Result on the web

<a href="https://link.springer.com/article/10.1007%2Fs00345-015-1611-7" target="_blank" >https://link.springer.com/article/10.1007%2Fs00345-015-1611-7</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00345-015-1611-7" target="_blank" >10.1007/s00345-015-1611-7</a>

Result language

angličtina

Original language name

Cranberry fruit powder (FlowensTM) improves lower urinary tract symptoms in men: a double-blind, randomized, placebo-controlled study.

Original language description

Background Lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia increase with age. To date, several medications are available to treat LUTS, including herbal remedies which offer less side effects but lack robust ef cacy studies. Methods This 6-month, randomized, double-blind, pla- cebo-controlled study aimed at evaluating the dose effect of 250 or 500 mg cranberry powder (FlowensTM) on LUTS and uro owmetry in men over the age of 45. A total of 124 volunteers with PSA levels <2.5 ng/mL and an inter- national prostate symptoms score (IPSS) score GREATER-THAN OR EQUAL TO8 were recruited and randomized. The primary outcome measure was the IPSS, evaluated at 3 and 6 months. Secondary out- come measures included quality of life, bladder volume (Vol), maximum urinary ow rate (Qmax), average urinary ow rate (Qave), ultrasound-estimated post-void residual urine volume (PVR), serum prostate-speci c antigen, sele- nium, interleukin 6, and C-reactive protein at 6 months. Results After 6 months, subjects in both FlowensTM groups had a lower IPSS (MINUS SIGN 3.1 and MINUS SIGN 4.1 in the 250- and * Emilie Fromentin e.fromentin@naturex.com 500-mg groups, p = 0.05 and p < 0.001, respectively) ver- sus the placebo group (MINUS SIGN 1.5), and a dose-response effect was observed. There were signi cant differences in Qmax, Qave, PVR, and Vol in the FlowensTM 500-mg group ver- sus baseline (p < 0.05). A dose-dependent effect on Vol was observed, as well as on PVR, for participants with a nonzero PVR. There was no effect on clinical chemistry or hematology markers. Conclusions FlowensTM showed a clinically relevant, dose-dependent, and signi cant reduction in LUTS in men over 45.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FJ - Surgery including transplantology

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

World Journal of Urology

ISSN

0724-4983

e-ISSN

—

Volume of the periodical

34

Issue of the periodical within the volume

3

Country of publishing house

DE - GERMANY

Number of pages

6

Pages from-to

419-424

UT code for WoS article

000371052400017

EID of the result in the Scopus database

—